Teva Pharma (TEVA) Investors: Mizuho Securities Reiterates Buy Rating, Sees $27.0000/Share; Range Resources (RRC) Sentiment Is 1.08

April 20, 2018 - By Peter Kolinski

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Logo

Range Resources Corp (RRC) investors sentiment decreased to 1.08 in 2017 Q4. It’s down -0.27, from 1.35 in 2017Q3. The ratio worsened, as 183 institutional investors started new or increased holdings, while 170 sold and reduced their stock positions in Range Resources Corp. The institutional investors in our database now hold: 230.02 million shares, down from 248.08 million shares in 2017Q3. Also, the number of institutional investors holding Range Resources Corp in top ten holdings decreased from 6 to 4 for a decrease of 2. Sold All: 51 Reduced: 119 Increased: 125 New Position: 58.

In analysts report shared with investors and clients on today, Mizuho Securities kept their Buy rating on Teva Pharma (NYSE:TEVA)‘s stock. The PT suggests a potential upside of 51.43% from firm’s last stock close price.

The stock increased 0.65% or $0.115 during the last trading session, reaching $17.825. About 270,514 shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 49.50% since April 20, 2017 and is downtrending. It has underperformed by 61.05% the S&P500.

Teva Pharmaceutical Industries Limited develops, makes, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The company has market cap of $18.13 billion. It operates through two divisions, Generic Medicines and Specialty Medicines. It currently has negative earnings. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Among 35 analysts covering Teva Pharma (NYSE:TEVA), 9 have Buy rating, 8 Sell and 18 Hold. Therefore 26% are positive. Teva Pharma has $86 highest and $8 lowest target. $28.73’s average target is 61.18% above currents $17.825 stock price. Teva Pharma had 149 analyst reports since July 21, 2015 according to SRatingsIntel. On Monday, September 11 the stock rating was upgraded by BTIG Research to “Buy”. The firm has “Sell” rating given on Tuesday, September 5 by Credit Suisse. The stock has “Hold” rating by Mizuho on Thursday, October 26. As per Monday, February 12, the company rating was upgraded by Credit Suisse. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Perform” rating given on Thursday, August 3 by Oppenheimer. Mizuho downgraded Teva Pharmaceutical Industries Limited (NYSE:TEVA) on Friday, February 10 to “Neutral” rating. The firm has “Buy” rating given on Thursday, February 15 by Mizuho. The rating was maintained by Barclays Capital on Tuesday, January 31 with “Equal Weight”. The stock has “Hold” rating by Cantor Fitzgerald on Thursday, August 3. The firm has “Hold” rating by Argus Research given on Tuesday, February 28.

Analysts await Teva Pharmaceutical Industries Limited (NYSE:TEVA) to report earnings on May, 10. They expect $0.62 earnings per share, down 39.81% or $0.41 from last year’s $1.03 per share. TEVA’s profit will be $630.47M for 7.19 P/E if the $0.62 EPS becomes a reality. After $0.91 actual earnings per share reported by Teva Pharmaceutical Industries Limited for the previous quarter, Wall Street now forecasts -31.87% negative EPS growth.

Ratings analysis reveals 100% of Range Resources’s analysts are positive. Out of 5 Wall Street analysts rating Range Resources, 5 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $50.0 while the high is $58.0. The stock’s average target of $54 is 287.93% above today’s ($13.92) share price. RRC was included in 5 notes of analysts from October 7, 2016. Instinet upgraded the shares of RRC in report on Monday, February 6 to “Buy” rating. Imperial Capital maintained the shares of RRC in report on Friday, October 28 with “Outperform” rating. R. F. Lafferty initiated it with “Buy” rating and $58.0 target in Wednesday, January 25 report. Goldman Sachs upgraded the shares of RRC in report on Monday, October 31 to “Buy” rating. JP Morgan upgraded the shares of RRC in report on Friday, October 7 to “Overweight” rating.

The stock decreased 2.25% or $0.32 during the last trading session, reaching $13.92. About 352,101 shares traded. Range Resources Corporation (RRC) has declined 48.60% since April 20, 2017 and is downtrending. It has underperformed by 60.15% the S&P500.

Since January 1, 0001, it had 1 buy, and 3 selling transactions for $228,453 activity.

Analysts await Range Resources Corporation (NYSE:RRC) to report earnings on April, 25 after the close. They expect $0.45 EPS, down 34.78% or $0.24 from last year’s $0.69 per share. RRC’s profit will be $110.46M for 7.73 P/E if the $0.45 EPS becomes a reality. After $0.22 actual EPS reported by Range Resources Corporation for the previous quarter, Wall Street now forecasts 104.55% EPS growth.

Range Resources Corporation (NYSE:RRC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>